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INTRODUCTION
Tumors of the small bowel are relatively rare in incidence. 
They account for only approximately 3-6% of all gastrointes-
tinal neoplasms and 1-3% of all gastrointestinal malignancy. 
Incidence of small intestinal cancer was estimated as 5,300 
new cases annually with an estimated 1,100 deaths in the Uni-
tes States.
1 According to autopsy data, approximately 40 differ-
ent histological types of tumors arise in the small bowel. The 
most frequent neoplasms are adenomas and mesenchymal 
tumors. Less common benign lesions include lipomas, angi-
omas, and hamartomas. Carcinoid tumor and adenocarcino-
ma are the most common small intestinal malignancies, with 
an annual incidence of 3.8 and 3.7 cases, respectively, per mil-
lion people in the United States, followed by lymphomas (1.1/ 
million) and sarcomas (1.3/million).
2 In Korea, the Annual re-
port of cancer statistics in Korea in 2008 reported the incid-
ence of small intestinal cancer 0.98% of all gastrointestinal 
malignancy.
3 In 2005 United States report,
4 the distribution of 
small bowel cancer histology was 44% carcinoid, 33% adeno-
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carcinoma, 15% lymphoma, and 7% gastrointestinal stromal 
tumor (GIST). Metastatic small intestinal cancers are from 
skin melanoma, colorectum, prostate, lung and breast. Multi-
ple factors influence on the relative infrequency of tumorigene-
sis in the small bowel; rapid small bowel (SB) transit time, a 
high concentration of the enzyme detoxifying carcinogen,
5 ab-
undant lymphoid tissue and high levels of IgA, alkaline pH and 
the lower bacterial load, and rapid turnover of the intestinal 
mucosa.
6 
Considering the literatures in the past were written before 
the introduction of newer small intestinal investigation mo-
dalities, the real incidence of small intestinal tumor may be 
higher than we had known. Recently we reported the overall 
frequency of small intestinal tumors as 4.3% in Korean na-
tional cohort of wireless capsule endoscopy (WCE) which 
was performed with indications including obscure gastroin-
testinal bleeding (OGIB), abdominal pain, weight loss, diar-
rhea, and so on.
7 Similarly in a recent large scale European 
study, WCE revealed tumors in small bowel in 2.4%.
8 This 
raises the possibility of increasing incidence of SB tumor in 
clinical practice with advance of new diagnostic technology. 
 
THE CLINICAL PRESENTATIONS  
OF SMALL INTESTINAL TUMORS
The clinical manifestations of small intestinal tumors are ge-
nerally vague and nonspecific. Nonspecific and vague symp-
toms include pain, nausea, and vomiting related to partial or 
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complete bowel obstruction. Bleeding or perforation may oc-
cur.
9,10 OGIB is the most common presentation of small in-
testinal tumors. In patients presenting OGIB, small intestinal 
tumors are diagnosed in around 6%.
11-14 Weight loss, which 
occurs in approximately 30% to 50% of patients, should alert 
the physician to search for underlying organic causes and lead 
to a more thorough diagnostic workup, especially in patients 
aged over (older than) 50-years-old. Unexplained abdominal 
pain can also be the presentation of small intestinal tumors. 
In a Korean study, 2 out of 110 patients revealed small intes-
tinal tumor as the causative lesion for unexplained abdomi-
nal pain in WCE evaluation.
15 Because their clinical presentat-
ion is vague, a high index of suspicion is the key to diagnose 
them. Overt symptomatic tumors are often at advanced stage 
and have metastasis in a half of cases. Coupled with these un-
discriminating presentations, the relative inaccessibility to 
the small bowel has been an obstacle in making a diagnosis. 
The majority of patients with small intestinal malignancies 
are diagnosed in the fifth or sixth decades of life. Patients with 
SB lymphomas are usually diagnosed a decade earlier.
16 For 
all histologic types, and as with colorectal and gastric cancer, 
men tend to have a slightly higher rate of affliction than wo-
men.
17,18 
Genetically predisposing conditions such as familial ade-
nomatous polyposis (FAP), hereditary non-polyposis colorec-
tal cancer (HNPCC), celiac disease, and Peutz-Jeghers syn-
drome (PJS) are associated with increased incidence of the 
small intestinal adenocarcinoma (Table 1). Celiac disease is 
also associated with the enteropathy associated T-cell lympho-
ma in the small bowel. Personal history of colorectal cancer 
and Crohn’s disease increase the possibility of development 
of small bowel adenocarcinoma. Acquired conditions includ-
ing biliary diversion, ileostomy stomas, pouches, and con-
duits increase the risk of small bowel adenocarcinoma.
5 It is 
also associated with the same carcinogens known to promote 
large bowel cancer such as a diet high in red meat, and alcohol 
and tobacco usage.
19 
 
Carcinoid tumor
Carcinoid tumor is the most common histological subtype 
in primary malignant small intestinal tumors, accounting for 
20% to 50% of the total.
2,16,20,21 The majority of small intestinal 
carcinoid tumors occur in the terminal ileum within 1 m from 
the ileocecal valve. Up to one third of patients have multiple 
tumors and patients with carcinoid tumors of the small bow-
el are at risk of a second gastrointestinal malignancy includ-
ing gastric, colorectal, and pancreatic cancers.
22 Because the 
majority of carcinoid tumors is small in size and grows very 
slowly, they are usually asymptomatic and are found inciden-
tally during exploratory laparotomy or autopsy. Occasionally 
patients complain of episodes of abdominal pain consistent 
with intermittent bowel obstruction. When the primary carci-
noid tumor reaches a size of 2 cm, the risk of metastasis to 
the liver increases substantially.
21 With liver metastases there 
may be manifestations of the carcinoid syndrome, character-
ized by episodic flushing, watery diarrhea, and wheezing. Pres-
ence of the carcinoid syndrome simplifies diagnosis. 
Carcinoid tumors of the small bowel are divided into two 
groups: tumors of the duodenum and upper jejunum and tu-
mors of the distal jejunum and ileum. In the former group, 
gastrin-cell (G-cell) tumors predominate, followed by soma-
tostatin-cell (D-cell) tumors, gangliocytic paraganglioma, 
and rarely, enterochromaffin-cell (EC-cell), serotonin-produc-
ing tumors. Conversely, endocrine tumors of the more distal 
segments of the small bowel are mostly EC-cell carcinoids.
 
Adenocarcinomas
Adenocarcinoma had historically been the most commonly 
diagnosed histological subtype of small intestinal tumors, but 
has recently been surpassed by carcinoid tumors according to 
the National Cancer Data Base.
4 It accounts for approximate-
ly 33% of all primary malignant small bowel tumors.
2,16,20,23 
The small bowel adenocarcinoma was located 56% in duode-
num, 16% in jejunum, and 13% in ileum. The exception to this 
presentation is seen in Crohn’s disease, where the majority of 
adenocarcinoma occurs in the ileum. The proximal location 
of most small intestinal adenocarcinomas may reflect the pre-
sence of higher concentrations of bile, previously linked to in-
creased risk for adenocarcinoma.
24
Adenocarcinomas of the small bowel and colon are similar 
in many ways, including their development from adenoma-
tous polyps and shared genetic susceptibility. Mutations in 
APC, K-ras, and p53 have all been demonstrated,
25 but unlike 
colon cancer, APC mutations are not common. Molecular an-
alysis of small intestinal adenocarcinoma has demonstrated 
the presence of high-microsatellite instability (MSI-H), asso-
ciated with defects in DNA mismatch repair, in almost 20% 
of cases.
26 Thus patients with small bowel adenocarcinomas 
Table 1. Risk Conditions for Small Intestinal Neoplasm
Clinical condition Type of small intestinal neoplasm
Familial adenomatous 
  polyposis
Adenocarcinoma
HNPCC Adenocarcinoma
Peutz-Jeghers syndrome Adenocarcinoma
Celiac disease Lymphoma (and adenocarcinoma)
Crohn’s disease Adenocarcinoma
Biliary diversion Adenocarcinoma
Melanoma of skin Melanoma
HNPCC, hereditary non-polyposis colorectal cancer.DY Cheung et al. 
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are at increased risk of developing colorectal cancers and vice 
versa.
27 Grossly, unlike ampullary and periampullary carcino-
mas, which are usually circumscribed and polypoid, small in-
testinal adenocarcinomas are usually large, annular, constrict-
ing, and centrally ulcerated masses with circumferential invol-
vement of the intestinal wall. Regarding the anatomical dis-
tribution, duodenum is most frequently involved (55%) and 
followed by jejunum (30%) and ileum (15%).
28 Microscopical-
ly, these tumors are very similar to their colonic counterparts, 
but with a higher proportion of poorly differentiated tumors. 
The prognosis of small intestinal adenocarcinoma is poor and 
the 5 year survival rate only remains at 25-30%.
29,30 
 
Primary gastrointestinal lymphomas
Small intestinal lymphoma constitutes 15-20% of all small 
intestinal neoplasms and 20-30% of all primary gastrointesti-
nal lymphomas. Ileum is the most common site (60-65%) in-
volved, followed by jejunum (20-25%), duodenum (6-8%) and 
other sites (8-9%).
19 The clinical presentation of small intesti-
nal lymphoma includes colicky abdominal pain, nausea, vomi-
ting, weight loss and rarely acute obstructive symptoms, in-
tussusceptions, perforation or diarrhea. Several types of lym-
phomas exist. Diffuse large B-cell lymphoma is most fre-
quently observed. T-cell lymphoma and follicular lymphoma 
are more frequent in small intestinal cases than in gastric cases. 
Macroscopically, small intestinal lymphomas present as poly-
poid, ulcerative (including stricturing, non-stricturing and an-
eurysmal forms on radiography), multiple lymphomatous po-
lyposis, diffuse, or other types. 
 
Mesenchymal tumors
Mesenchymal tumors of the small bowel encompass a va-
riety of benign and malignant tumors. With recent advances 
in immunohistochemistry, tumors lack of smooth muscle dif-
ferentiation can be differentiated from leiomyoma and leio-
myosarcoma. Spindle cell tumors arising from interstitial cells 
of Cajal, the cells that control intestinal motility, is nominated 
as GIST.
31 GISTs are found most commonly in the stomach (ap-
proximately two thirds) followed by the small bowel (appro-
ximately one third).
31 The size and shape varies in stomal tu-
mors. Commonly, they are dome-shaped and submucosal 
with or without a central ulceration, or they may be large, fun-
gating tumors that involve surrounding organs. Histological-
ly, GISTs are essentially identical to their more frequent gastric 
counterparts, although epithelioid lesions are rather uncom-
mon. GISTs are invariably immunoreactive for CD117 (KIT).
31 
Many GISTs have a demonstrable c-kit gene abnormality that 
can be therapeutically targeted using specific tyrosine kinase 
inhibitors. The factors predicting malignant GIST are size and 
mitotic or proliferative activity. In general, tumors over 5 cm 
in diameter and/or mitotic count greater than five mitoses per 
50 high power field (HPF) are potentially malignant GIST. 
Smooth muscle neoplasms include leiomyoma and leiomyo-
sarcoma. The smooth muscle phenotype must be immunohis-
tochemically confirmed, as should the lack of CD117 (KIT) 
expression. Leiomyomas are usually small (<1 cm in diame-
ter), well circumscribed, and submucosal lesions found inci-
dentally and comprised of bland spindle cells showing low or 
moderate cellularity, mild or no cytologic atypia, and rare if 
any mitoses. However, leiomyosarcomas are generally larger 
tumors that may extend to involve adjacent structures and at 
times exhibit foci of hemorrhage or necrosis. Histologically, 
they can be distinguished from their benign counterpart by 
their increased cellularity, nuclear atypia, mitotic activity (usu-
ally >5/10 HPF), and tumor cell necrosis. 
 
Melanoma 
Intestinal melanomas can be primary tumors but metasta-
ses from cutaneous, ocular, or anal melanomas are more li-
kely to happen.
32,33 Metastatic lesions commonly involve jeju-
num and ileum and form multiple polypoid submucosal mas-
ses, less commonly as single mass. Masses are pigmented or 
amelanotic and the ulceration is commonly accompanied. The 
diagnosis of intestinal metastasis is often made far past to the 
early stage. A half of the patients with intestinal metastasis 
present extraintestinal metastasis at the time of diagnosis.
34 
Even after the curative surgical excision of primary cutaneous 
melanoma, intestinal metastasis is diagnosed after 6 months 
to 90 months.
35,36 Enteroclysis is accepted as standard diagnos-
tic method and positron emission tomography (PET) imaging 
can improve detection of melanoma metastases to the small 
bowel. However, radiologic modalities such as ultrasonogra-
phy, upper gastrointestinal series (UGIS)/small bowel follow-
through (SBFT), computed tomography (CT), PET yields over 
all detection rate of as low as 10-20%.
37 Various treatment st-
rategies have been tried in patients with intestinal melanoma, 
surgical removal of intestinal metastases is the treatment of 
choice in patients with resectable tumors. No systemic therapy 
improves survival in patients with melanoma metastatic to the 
bowel; thus, the prognosis for these patients is poor. 
 
HOW TO DIAGNOSE SMALL INTESTINAL 
TUMOR
The diagnostic processes directed by the clinical presenta-
tion often start from the simplest examination modalities and 
findings are often vague and inconclusive. It has been usual 
that it takes 6 to 9 months to reach the final diagnosis.
9,38 In 
advanced or complicated patients, simple abdominal radiogra-
phy may reveal evidence of a small bowel obstruction or free 16  Clin Endosc 2011;44:13-21
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air, prompting an exploratory laparotomy. Patients with the re-
latively chronic symptoms of abdominal pain, nausea, vomit-
ing, weight loss, and signs of gastrointestinal bleeding have 
usually undergone an unrevealing workup including colo-
noscopy, esophagogastroduodenoscopy (EGD), and abdomi-
nal CT. 
The UGIS/SBFT and enteroclysis
UGIS/SBFT remains the most commonly used method to 
examine the small bowel. It is relatively easy to carry out and 
makes easily tolerable discomfort to patients. UGIS/SBFT 
can detect the small intestinal ulcer, mass and intussusceptions 
but the sensitivity of small intestinal tumor diagnosis is usu-
ally around 30-44%.
39 Especially for OGIB, the diagnostic yield 
reaches only 5%. 
Conventional enteroclysis employing double contrast me-
thod showed better sensitivity for small intestinal disease and 
has been accepted as the diagnostic standard. For OGIB, the 
overall diagnostic yield of enteroclysis is around 10-20%. For 
small intestinal tumors, the sensitivity reached up to 90% in 
comparison to 33% of SBS/SBFT.
40 However, enteroclysis has 
several fundamental limitations; it cannot visualize the lumi-
nal surface directly; it can miss the lesions of small size or le-
sions having continuous mucosal lining with adjacent mucosa; 
and it need highly skilled radiologist as well as makes signifi-
cant discomfort to patient. In general, the contribution of en-
teroclysis to small intestinal tumor diagnosis occupies 50-
60% only.
41 
 
CT
Though the advance of CT technology has allowed data 
acquisition over the entire abdomen in thin slices within one 
breath-hold, leading to fewer peristaltic and breathing arti-
facts, conventional CT scans detect only large size of intestinal 
tumors, at least over 1.0 cm in diameter. CT enteroclysis (CTE) 
is used to perform enhanced CT scanning and image post-
processing after the small bowel is distended by administrat-
ing a high volume of contrast medium orally or via a nasojeju-
nal catheter. It is easy to perform and produce reduced dis-
comfort and less complication. The best merit for CTE lies in 
the fact that it not only provides the picture of the luminal side 
of mucosa but also provide the information about the changes 
in adjacent and related organs and structures. CTE can de-
tect the mucosal changes, the cavitation or thickening of the 
wall, related lymph nodes status, mesentery, mesenteric vessels 
and the other organ structures. It helps us make an accurate pre-
operative staging and design an appropriate treatment plan.
42 
In view of easy and safe procedure, CTE become the pri-
mary choice for the detection and localization of small intes-
tinal tumors.
43 One pro-study showed that CTE has a high sen-
sitivity (100%) and specificity (95%) in the diagnosis of small 
intestinal diseases including tumors, Crohn’s disease, small 
intestinal tuberculosis, small intestinal lymphoma associated 
with celiac disease, and intestinal obstruction.
44 Regarding the 
size, CTE can detect tumors that are only 5 mm in diameter. 
The negative and positive predictive value of CTE for carcinoid 
tumor in patients with carcinoid symptoms were 100% and 
94.7%, respectively.
45 
 
Magnetic resonance imaging (MRI) 
MRI has the power to produce excellent soft tissue contrast 
and multiplanar imaging without radiation exposure. With 
the introduction of fast imaging techniques and improvement 
of contrast agents, MR enteroclysis (MRE) has been widely 
applied for the visualization of small intestinal diseases. It can 
not only be used to observe the mucous membrane but also 
reveals the pathological changes around the bowel. MRE can 
easily display small intestinal structures, especially in tumors 
with intestinal obstruction based on the signal difference ge-
nerated by intestinal wall and luminal contrast agents. Recent 
study showed 95% of overall diagnostic accuracy for small 
intestinal tumors.
46
 
Endoscopy 
Gastroduodenal endoscopy is extremely accurate in iden-
tifying lesions proximal to the ligament of Treitz or in the ter-
minal ileum. Push enteroscopes can reach and detect lesions 
located in the proximal jejunum, but not those in the mid to dis-
tal jejunum and ileum. Sonde enteroscopy, which is a 2,560 
mm balloon-tipped endoscope, relies on small bowel peri-
stalsis to propel the endoscope through the small bowel. Sev-
eral studies reported that it is successful in visualizing up to 
70% of the small bowel mucosa. The limitations of Sonde en-
teroscopy are need of expensive enteroscope, time consuming 
procedure up to 8 hours, and the inability to obtain biopsies. 
Two new endoscopic methods were introduced in 21st cen-
tury. WCE travels along the small bowel and acquires over 
50,000 images during 8-12 hour period. WCE can be perform-
ed in outpatient clinic and visualize the entire small bowel in 
a non-invasive manner (Fig. 1). Capsule retention may occur 
in points of pathology but not in normal condition.
47 In general, 
the diagnostic yield of WCE in OGIB reaches up to 50-75%, 
higher in comparison with UGIS/SBFT and enteroclysis.
48 In 
comparison with the push enteroscopy, WCE showed higher 
diagnostic yield (50-67.2% for WCE and 20-28% for push en-
teroscopy).
49-51 In comparison with double balloon enteros-
copy (DBE), the diagnostic yield of WCE was superior to that 
of DBE with one side approach and equivalent to that of DBE 
with both side approach.
52 The detection rate of small intesti-
nal tumors in WCE which is carried out for various kinds of DY Cheung et al. 
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indications is around 4%.
7,8 Most common indication for WCE 
is OGIB. In comparison with other conventional radiologic 
studies, exclusive detection rate of small bowel tumor by WCE 
was reported as 52.6% (30 out of 57)
7 to 65.2% (15 out of 23).
53 
However, WCE has also limitations. WCE moves passively by 
the intestinal peristalsis, WCE can miss the luminal lesion due 
to improper bowel preparation, presence of blood and rapid 
capsule transit. And tissue biopsy is not possible with WCE. 
Balloon-assisted enteroscopy encompassing DBE and sin-
gle balloon enteroscopy (SBE) was introduced in a decade ago. 
Like conventional endoscopies, DBE and SBE both allow di-
rect and controlled visualization of the intestinal lumen. Re-
garding the range of examination, DBE and SBE can examine 
the whole length of the small bowel via both oral and anal ap-
proach. There are several factors which affect the completion 
of examination, including the procedure itself and the deci-
sion of operator. The overall completion of the small intestinal 
examination ranges 11.0-57.1%.
54,55 The strength of DBE and 
SBE lies in the ability of tissue acquisition of lesion and sim-
ple therapeutic maneuvers such as clipping, polypectomy and 
cauterization are possible. In practice, the uses of DBE and 
SBE are confined to the conditions that suggest pathology in 
the small bowel and possibly need a therapeutic procedure. 
In a recent randomized controlled study, the overall diagnos-
tic yield in various indications including OGIB reaches 50.0-
61.1% and therapeutic outcomes reaches 27.8-35.0%.
55 Re-
garding the detection of tumors in the small bowel, the small 
intestinal tumor or polyp were detected in 6-10%.
55 In a Ko-
rean study, 13.8% of DBE procedures revealed small intesti-
nal tumors regardless the indications for procedure
12 and 
7-20% in other literatures.
11 In a study focusing on OGIB,
56 
the diagnostic yield was 45% and small intestinal tumor was 
detected in 13%. Among the patients with findings, 76% re-
ceived endoscopic treatment.
56 This is higher than that of 
WCE. It may result from the better control of visualization and 
patient selection difference. DBE can detect more small bowel 
tumors which are missed with WCE. In literature, among 18 
small bowel tumors detected with DBE, the capsule identified 
lesions in only one third of the patients and missed all four 
cases of adenocarcinoma.
57 Several studies have reported the 
usefulness of DBE in detecting and treating adenomatous pol-
yps in the small bowel in patients at high risk such as FAP 
and PJS.
58,59 The limitations of DBE are following; the complete 
small intestinal examination is not always possible; the dis-
comfort, radiation exposure and possible complications are 
not negligible. Due to the limitations mentioned above, DBE 
or SBE as the first-line approach is not prudent in screening 
examination and elective diagnostic process. However, in pa-
tients at high risk and with proven tumors in WCE, DBE and 
SBE may offer better diagnostic yield and can provide thera-
peutic options. 
 
Other modalities
There is no role for transcutaneous abdominal ultrasonog-
raphy in the evaluation of patients with suspected small intes-
tinal pathology except in pediatric patients with suspected in-
tussusception, where the classic target sign can be seen. 
111In-
dium octreotide imaging (octreotide scan) is a very useful te-
chnique when carcinoid tumor is suspected. The majority of 
carcinoid tumor cells express somatostatin receptors that bind 
the radio-labeled octreotide. Octreotide scanning has a 90% 
sensitivity rate for localizing carcinoid tumors in patients with 
the carcinoid syndrome and a 60% sensitivity rate in patients 
lacking the carcinoid syndrome.
60
 
SURVEILLANCE OF THE SMALL  
INTESTINAL TUMORS FOR PATIENTS  
AT RISK
 
On the bases of known risk factors for small intestinal ma-
Fig. 1. Small intestinal tumors on wireless capsule endoscopy. (A) Epithelial mass with ulceration, suggestive of adenocarcinoma. (B) Sub-
epithelial mass with top ulceration, proved as gastrointestinal stromal tumor on surgical pathology. (C) Multiple epithelial mass with fungoid 
growth, diagnosed histologically as lymphoma.
A   B   C  18  Clin Endosc 2011;44:13-21
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lignant tumors, patients at risk might have benefit from pro-
per surveillance (Table 1). Patients with familial and nonfa-
milial polyposis syndrome are at increased risk of small in-
testinal cancer as well as colorectal cancer. The risk of small 
intestinal adenocarcinoma varies according to the types of 
polyposis syndrome. Not only adenomatous polyp, but ham-
artomatous polyps also have the foci of adenoma inside and 
these are associated with an increased risk of adenocarcinoma 
development. FAP is a well recognized condition in which 
adenomatous polyps develop in the region of the ampulla of 
Vater in 70-90% of patients, and 5-7% of adenomatous polyps 
undergo malignant change into adenocarcinoma.
61 Predictors 
for cancer risk described by Spigelman et al.
62 include the 
number, size, histology and degree of dysplasia (Table 2). In 
10 year follow-up of duodenal polyps in FAP patients, Spigel-
man stage IV polyps developed into cancer in 36.4%.
63 To re-
duce the risk of cancer from duodenal polyps, surveillance with 
duodenoscopy is recommended. In other site of the small 
bowel, jejunum and ileum, adenomatous polyps are detected 
in 75% of patients with FAP,
64 but the cancer development has 
been rarely reported. Until now, there is no available data for 
usefulness of the small intestinal surveillance in FAP. 
HNPCC is caused by germ line mutations of one of the mis-
match repair genes, usually MLH1, MSH2, and MSH6. Af-
fected individuals are highly susceptible to colorectal and en-
dometrial cancer as well as small intestinal cancer. In 34-78% 
of patients, small intestinal cancer was the first malignant ma-
nifestation of HNPCC syndrome.
65 For patients with HN-
PCC, the cumulative risk of small intestinal adenocarcinoma 
was estimated as 3-4% and it is more than 100 times the risk 
of the general population.
65,66 This is similar to the lifetime risk 
of colorectal cancer in general population, and for which the 
screening surveillance is widely accepted as prudent. As a 
Table 2. Classification of the Severity of Duodenal Polyposis in 
FAP
62
Points
1 2 3
No. of polyps 1-4 5-20 >20
Size of polyp (mm) 1-4 5-10 >10
Histology Tubular Tubulovillous Villous
Dysplasia Mild Moderate Severe
Stage Points
Duodenal cancer risk (%) 
in 10 year follow-up
63
0 0 0
I 1-4 0
II 5-6 02.3
III 7-8 02.4
IV 9-12 36.4
FAP, familial adenomatous polyposis.
known risk factor, older aged population is more likely to have 
small intestinal adenocarcinoma. However, the patients with 
HNPCC present small intestinal adenocarcinoma 10-20 years 
earlier than the patients with sporadic small intestinal can-
cers which are diagnosed in sixth or seventh decades of life. 
And more than 10% of patients were diagnosed with small 
intestinal cancer before the age of 30 years.
67 Male gender is 
slightly more affected than female. Localization in the small 
bowel is almost even in duodenum (45%), jejunum (29%), and 
ileum (12%).
68 EGD surveillance in patients over 30 years old 
with HNPCC is recommended to detect both duodenal and 
gastric cancer which is also at increased risk in HNPCC.
68 How-
ever, the rest of the small intestinal area cannot be examined 
with EGD. Regarding the small intestinal surveillance, we 
still need more evidence and consideration about cost/risk-
benefit aspect. Early diagnosis and treatment of small intesti-
nal adenoma/cancer in patients with HNPCC syndrome will 
probably improve prognosis. WCE can potentially detect 
these tumors in the presymptomatic stage, which is tentatively 
associated with better outcomes and several life-years possi-
bly be gained. In a WCE study with 35 asymptomatic HNPCC 
patients, one adenocarcinoma and 2 adenomas were diag-
nosed.
69 
PJS is an inherited polyposis syndrome in which multiple 
characteristic polyps occur in the gastrointestinal tract, asso-
ciated with mucocutaneous pigmentation, especially of the 
vermilion border of the lips. It is inherited in an autosomal 
dominant manner and is caused by a germline mutation in 
the STK11 (LKB1) gene. Polyps are found throughout the 
gastrointestinal tract but most are in the small bowel (60-
90%) and colon (50-64%).
70 Gastrointestinal polyps may cause 
gastrointestinal bleeding, anemia and abdominal pain due to 
intussusception, obstruction or infarction. Polyp-related symp-
toms usually arise in childhood and are seen by the age of 10 
years in 33% and by 20 years in 50%. Regarding the cancer de-
velopment in gastrointestinal tract, though it has been pro-
posed that the hamartoma-adenoma-carcinoma pathway ex-
ists,
71 the nature of carcinogenesis in PJS remains controver-
sial. Based on epidemiologic and molecular genetic studies, 
it is widely accepted that there is increased risk of various can-
cers in PJS. Overall life time risk of any cancer reaches to 85-
93% in PJS.
72,73 Breast cancer (54%) and colon cancer (39%) 
are the most common cancers, followed by pancreatic cancer 
(36%).
72 Life time incidence for the small bowel cancer is 1.7%
73 
to 13%.
72 And the risk of cancer development increases rap-
idly after the age of 50.
73 Though the consensus is not concrete, 
routine screening for upper gastrointestinal tract and colon 
is recommended, beginning at the age of 18, with 2-3 year in-
terval.
74-77 For small intestinal surveillance, the main indication 
is the prevention of intussusceptions and the need for emer-DY Cheung et al. 
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gency laparotomy. Though the data are limited, 68% of pa-
tients with PJS experience laparotomy by age of 18 and 30% 
at the age of 10.
78 Recent proposal recommends small intesti-
nal surveillance with WCE, beginning at the age of 18, with 3 
year interval.
74 
And to prevent the need of intussusceptions laparotomy in 
childhood, additional baseline examination with WCE is also 
recommended at the age of 8. For this purpose, MRE and SB-
FT which show no difference in detection of polyp over 1.0 cm 
size can be reasonable alternatives.
74 
Patients with celiac disease have an increased risk for enter-
opathy-associated lymphomas as well as adenocarcinoma.
79 
Because the risk for both of these malignancies appears to be 
very small (<1%), there is no established role for surveillance 
endoscopy.
80 However, the possibility should be considered in 
patients who have had celiac disease for many years. Those pa-
tients who become symptomatic after years of quiescent dis-
ease while strictly adhering to a gluten-free diet should be 
thoroughly investigated for a small intestinal malignancy.
Similarly, there is no established surveillance protocol for 
small intestinal cancer in patients with Crohn’s disease. How-
ever, the development of a symptomatic small bowel stricture 
that does not respond to steroids should be suspected of har-
boring a malignancy and should be surgically resected.
81 Also, 
presentation of patients with longstanding quiescent disease 
with small bowel obstruction suggests a newly developed small 
intestinal cancer.
In patients with cutaneous melanoma, intestinal metastasis 
is not uncommon condition and early detection of intestinal 
metastasis can possibly improve the chance of cure. Trial 
with WCE showed 20.4% detection rate of intestinal metasta-
sis in cutaneous melanoma patients with intestinal blood loss 
and 28.6% in stage IV disease regardless of intestinal blood 
loss.
82 Among those, a half of patients underwent intestinal 
surgery for metastasis. However, there are still limited data to 
evaluate the effect of WCE on the survival and a reasonable pro-
posal to surveillance still doesn’t exist. 
 
CONCLUSIONS
Cancers arising in the small bowel pose a unique and diffi-
cult challenge to gastroenterologists, surgeons, and hematoon-
cologists. The inaccessibility to the small bowel has now been 
overcome with newer CT/MR imaging and endoscopic mo-
dalities such as balloon assisted enteroscopy and capsule en-
doscopy. Newer diagnostic modalities provide clear and fine 
anatomical visualization of the small bowel and are approved 
to improve the diagnostic sensitivity and accuracy. Currently 
available data regarding the usefulness of new methods in di-
agnosis of small intestinal tumors are still limited, however, 
the prospective up to date are positive. With this recent diag-
nostic advance, the issues surrounding the screening and sur-
veillance of small intestinal tumors in patient at risk should be 
assessed and the clinical outcomes of small intestinal tumors 
can possibly improve also. 
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